1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Embolic Protection Device Clinical Trials 6
2.1 Embolic Protection Device Clinical Trial By Equipment Type 6
2.2 Embolic Protection Device Clinical Trials By Trial Phase and Trial Status 7
2.3 Embolic Protection Device Pipeline Products By Development Stage 8
2.4 Embolic Protection Device Pipeline Products By Therapy Area 9
2.5 Embolic Protection Device Pipeline Products By News Summary 10
2.6 Embolic Protection Device MO.MA 11
2.6.1 DESERVE: Diffusion Weighted-MRI Based Evaluation Of The Effectiveness Of Endovascular Clamping During Carotid Artery Stenting With The Mo.Ma Device A Prospective, Multicenter Study 11
2.6.2 Effect Of Two Different Neuroprotection Systems On Microembolization During Carotid Artery Stenting 13
2.6.3 ARMOUR: Proximal Protection With The MO.MA Device During Carotid Stenting 14
2.7 Embolic Protection Device Emboshield Pro Rapid Exchange Embolic Protection System Generation 5 17
2.7.1 PROTECTed Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA) 17
2.7.2 Carotid Angioplasty And Stenting Versus Endarterectomy In Asymptomatic Subjects Who Are At Standard Risk For Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease 20
2.8 Embolic Protection Device GORE Embolic Filter 21
2.8.1 EMBOLDEN Clinical Study 21
2.9 Embolic Protection Device FiberNet Distal Protection System 22
2.9.1 Fibernet Renal Artery Embolic Protection Study: A Prospective, Single-Arm Feasibility Trial Of Renal Artery Distal Protection Using The Lumen Biomedical Fibernet Embolic Protection System 22
3 Recent Developments 24
3.1 Product News 24
3.1.1 Jun 12, 2009: Abbott Launches Emboshield NAV6 Embolic Protection System 24
3.1.2 Mar 10, 2009: GORE Flow Reversal System Treats First Patient At Hahnemann University Hospital 24
3.1.3 Feb 09, 2009: Gore Receives 510 (k) Clearance For GORE Flow Reversal System 25
3.1.4 Jan 16, 2009: First Patient Enrolled In W.L. Gore & Associates’ Gore EMBOLDEN Clinical Study 25
3.1.5 Dec 31, 2008: INVATEC's New Mo.Ma Ultra Introduced At ICCA 08, Frankfurt 26
3.1.6 Nov 19, 2008: Lumen Biomedical's FiberNet Embolic Protection System Receives FDA Approval For Carotid Artery Stenting 26
3.1.7 Oct 16, 2008: EPIC Carotid Stent Trial Reveals Lowest Sroke Rates With Distal Protection To Date 26
3.1.8 Oct 15, 2008: Lumen Biomedical To Present EPIC Carotid Stenting Trial At TCT Conference 27
3.1.9 Oct 10, 2008: W. L. Gore & Associates Receives FDA Approval For Gore EMBOLDEN Clinical Study 27
3.1.10 Jul 25, 2007: St. Jude Medical Announces FDA Clearance Of The Proxis Embolic Protection System 27
3.2 Product Approvals 28
3.2.1 Feb 09, 2009: Gore Receives 510 (k) Clearance For GORE Flow Reversal System 28
3.2.2 Nov 19, 2008: Lumen Biomedical's FiberNet Embolic Protection System Receives FDA Approval For Carotid Artery Stenting 28
3.3 Clinical Trials 28
3.3.1 Jan 16, 2009: First Patient Enrolled In W.L. Gore & Associates’ Gore EMBOLDEN Clinical Study 28
3.3.2 Oct 16, 2008: EPIC Carotid Stent Trial Reveals Lowest Sroke Rates With Distal Protection To Date 29
3.3.3 Oct 15, 2008: Lumen Biomedical To Present EPIC Carotid Stenting Trial At TCT Conference 29
3.3.4 Oct 10, 2008: W. L. Gore & Associates Receives FDA Approval For Gore EMBOLDEN Clinical Study 30
4 Appendix 31
4.1 Methodology 31
4.1.1 Coverage 32
4.1.2 Secondary Research 32
4.1.3 Primary Research 32
4.1.4 Expert Panel Validation 33
4.2 Contact Us 33
4.3 About Global Markets Direct 33
4.4 Disclaimer 33

1.1 List of Tables
Table 1: Embolic Protection Device Clinical Trial By Equipment Type 6
Table 2: Embolic Protection Device Clinical Trials By Trial Phase and Trial Status 7
Table 3: Embolic Protection Device Pipeline Products By Development Stage 8
Table 4: Embolic Protection Device Pipeline Products By Therapy Area 9
Table 5: Embolic Protection Device Pipeline Products By News Summary 10
Table 6: MO.MA - DESERVE: Diffusion Weighted-MRI Based Evaluation Of The Effectiveness Of Endovascular Clamping During Carotid Artery Stenting With The Mo.Ma Device A Prospective, Multicenter Study 11
Table 7: MO.MA - Effect Of Two Different Neuroprotection Systems On Microembolization During Carotid Artery Stenting 13
Table 8: MO.MA - ARMOUR: Proximal Protection With The MO.MA Device During Carotid Stenting 14
Table 9: Emboshield Pro Rapid Exchange Embolic Protection System Generation 5 - PROTECTed Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA) 17
Table 10: Emboshield Pro Rapid Exchange Embolic Protection System Generation 5 - Carotid Angioplasty And Stenting Versus Endarterectomy In Asymptomatic Subjects Who Are At Standard Risk For Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease 20
Table 11: GORE Embolic Filter - EMBOLDEN Clinical Study 21
Table 12: FiberNet Distal Protection System - Fibernet Renal Artery Embolic Protection Study: A Prospective, Single-Arm Feasibility Trial Of Renal Artery Distal Protection Using The Lumen Biomedical Fibernet Embolic Protection System 22

1.2 List of Figures
Figure 1: Global Markets Direct Methodology 31